GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (OTCPK:HTGMQ) » Definitions » Beneish M-Score
中文

HTG Molecular Diagnostics (HTG Molecular Diagnostics) Beneish M-Score : 0.00 (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is HTG Molecular Diagnostics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for HTG Molecular Diagnostics's Beneish M-Score or its related term are showing as below:

During the past 11 years, the highest Beneish M-Score of HTG Molecular Diagnostics was 0.00. The lowest was 0.00. And the median was 0.00.


HTG Molecular Diagnostics Beneish M-Score Historical Data

The historical data trend for HTG Molecular Diagnostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HTG Molecular Diagnostics Beneish M-Score Chart

HTG Molecular Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 222.37 -3.20 -3.97 1.23 -3.10

HTG Molecular Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.92 104.51 7.77 -3.10 -2.58

Competitive Comparison of HTG Molecular Diagnostics's Beneish M-Score

For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HTG Molecular Diagnostics's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where HTG Molecular Diagnostics's Beneish M-Score falls into.



HTG Molecular Diagnostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of HTG Molecular Diagnostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 2.1047+0.528 * 2.3924+0.404 * 0.7859+0.892 * 0.7181+0.115 * 0.9567
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1608+4.679 * -0.283637-0.327 * 1.4585
=-2.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Total Receivables was $1.13 Mil.
Revenue was 1.033 + 2.439 + 1.251 + 1.492 = $6.22 Mil.
Gross Profit was -0.117 + 0.408 + 0.58 + 0.477 = $1.35 Mil.
Total Current Assets was $9.19 Mil.
Total Assets was $10.87 Mil.
Property, Plant and Equipment(Net PPE) was $1.42 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.49 Mil.
Selling, General, & Admin. Expense(SGA) was $14.46 Mil.
Total Current Liabilities was $6.56 Mil.
Long-Term Debt & Capital Lease Obligation was $0.42 Mil.
Net Income was -5.055 + -4.693 + -4.516 + -5.888 = $-20.15 Mil.
Non Operating Income was -0.04 + 0 + 0.008 + -0.206 = $-0.24 Mil.
Cash Flow from Operations was -4.364 + -2.023 + -4.595 + -5.85 = $-16.83 Mil.
Total Receivables was $0.75 Mil.
Revenue was 1.184 + 2.877 + 2.52 + 2.074 = $8.66 Mil.
Gross Profit was 0.329 + 1.522 + 1.537 + 1.103 = $4.49 Mil.
Total Current Assets was $25.42 Mil.
Total Assets was $28.46 Mil.
Property, Plant and Equipment(Net PPE) was $2.19 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.71 Mil.
Selling, General, & Admin. Expense(SGA) was $17.35 Mil.
Total Current Liabilities was $8.49 Mil.
Long-Term Debt & Capital Lease Obligation was $4.05 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.132 / 6.215) / (0.749 / 8.655)
=0.18214 / 0.08654
=2.1047

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4.491 / 8.655) / (1.348 / 6.215)
=0.518891 / 0.216895
=2.3924

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (9.187 + 1.421) / 10.866) / (1 - (25.417 + 2.187) / 28.464)
=0.023744 / 0.030214
=0.7859

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=6.215 / 8.655
=0.7181

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.708 / (0.708 + 2.187)) / (0.488 / (0.488 + 1.421))
=0.24456 / 0.255631
=0.9567

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(14.462 / 6.215) / (17.35 / 8.655)
=2.326951 / 2.004622
=1.1608

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.423 + 6.559) / 10.866) / ((4.046 + 8.494) / 28.464)
=0.642555 / 0.440556
=1.4585

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-20.152 - -0.238 - -16.832) / 10.866
=-0.283637

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

HTG Molecular Diagnostics has a M-score of -2.58 suggests that the company is unlikely to be a manipulator.


HTG Molecular Diagnostics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of HTG Molecular Diagnostics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


HTG Molecular Diagnostics (HTG Molecular Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3430 E. Global Loop, Tucson, AZ, USA, 85706
HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.
Executives
Stephen Barat officer: Senior VP of Therapeutics C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Thomas W. Dubensky director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
L5 Capital Inc. 10 percent owner 1 FIRST CANADIAN PLACE, 39TH FLOOR, TORONTO A6 M5X 1H3
Christopher P Kiritsy director
Byron Lawson officer: SVP/Chief Commercial Officer C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Tim B Johnson director, officer: President & CEO
Laurence W Lytton 10 percent owner 467 CENTRAL PARK WEST, NY NY 10025
Laura Lee Godlewski officer: VP of Accounting and Reporting C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Shaun D Mcmeans officer: VP, Finance & Admin. & CFO 3708 E COLUMBIA STREET, SUITE #110, TUCSON AZ 85714-3413
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Nv Qiagen 10 percent owner HULSTERWEG 82, PL VENLO P7 5912
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Don M Hardison director